Free website hits

Good morning, one and all. Damian Garde here, filling in for Ed Silverman on this truncated week before that big holiday. Perhaps you’ve got a few days off on the horizon, or maybe you’re working straight through the shortened days of December. Either way, here’s hoping the comforts of home haven’t lost all their charm over these many months spent indoors. In the meantime, here, as always, are some tidbits to get your day started. …

Moderna’s (MRNA) Covid-19 vaccine got authorization from the Food and Drug Administration for emergency use, a week after a vaccine from Pfizer (PFE) and BioNTech (BNTX) received the same designation, STAT tells us. The vaccine is now rolling out across the U.S., and Moderna expects to ship about 20 million doses before the end of the year, enough to vaccinate 10 million people.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]